GlassScriptPhysician profile
Leah M Ebben
NPI 1124693395
$7,122.34
in general payments reported to CMS, 2019-2025
21 companies · $2,042 in 2025
The $2,042 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $210 · 2023: $993 · 2024: $3,877 · 2025: $2,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,536 · Travel and Lodging: $1,306 · Consulting Fee: $720 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,535.75 |
| Travel and Lodging | $1,306.12 |
| Consulting Fee | $720.00 |
| Education | $350.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $3,657.60 | 2023-2025 | Epkinly |
| Abbvie INC. | $674.41 | 2023-2025 | |
| Incyte Corporation | $437.61 | 2023-2025 | Monjuvi, Jakafi, Monjuvi |
| Janssen Biotech, INC. | $390.44 | 2023-2024 | Darzalex, Tecvayli |
| Pfizer INC. | $314.01 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $308.10 | 2022-2023 | Reblozyl, Onureg |
| Genzyme Corporation | $191.48 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $125.50 | 2025 | Xpovio |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Beone Medicines USA, INC. | $124.50 | 2025 | Brukinsa |
| Eisai INC. | $124.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $103.38 | 2024 | Calquence |
| Geron Corporation | $102.96 | 2025 | Rytelo |
| Amgen INC. | $101.41 | 2025 | Blincyto |
| Kite Pharma, INC. | $93.50 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $85.00 | 2025 | |
| Novocure INC. | $80.91 | 2024 | Optune |
| Celgene Corporation | $31.89 | 2025 | Opdivo |
| Merck Sharp & Dohme LLC | $21.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.57 | 2024 | |
| Genentech USA, INC. | $13.46 | 2025 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Ebben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.